CRBU supply chain intelligence for Caribou Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Caribou Biosciences, Inc. (CRBU) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INTELLIA-THERAPEUTICS-INC | INTELLIA-THERAPEUTICS-INC | 92% | we have primarily funded our operations through proceeds from the sales of our capital stock, revenue from our license and collaboration agreements, and proceeds from the sale of shares of Intellia T… |
| CMOS | CMOS | 90% | We expect to continue to rely on our CMOs for manufacturing our clinical trial materials |
| ADAPY | ADAPY | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ADAPY graph: Reciprocal relationship from CRBU graph: untries where our product candida… |
| ALLO | Allogene Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ALLO g… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ARTV g… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | Reciprocal relationship from ATRA graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whethe… |
| BMY | Bristol-Myers Squibb Company | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| DTIL | Precision BioSciences, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CRBU graph: untries where our product candidate… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory r… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Con… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domestic or foreign, governmental or commercial… |
| NTLA | Intellia Therapeutics, Inc. | 72% | cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domestic or foreign, governmental or commercial… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from CRBU graph: cts from countries where our produc… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CRBU graph: untries where our product candidate… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whet… |
| ADAPY | ADAPY | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ALLO | Allogene Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | Reciprocal relationship from ATRA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ATRA graph: Reciprocal relationship from CRBU graph: untries where our product candidate… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| BMY | Bristol-Myers Squibb Company | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from BMY grap… |
| DTIL | Precision BioSciences, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domestic or foreign, governmental or commercial… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, t… |
| NTLA | Intellia Therapeutics, Inc. | 72% | mulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is recorded in the statements of operations. Repairs and maintenance are expensed as incurred. … |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from CRBU graph: mulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is recorded i… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from RNAC g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CRBU-DEBT | Debt stack $26.9M | 90% | Market cache reports total debt of $26.9M. |
| CRBU-DEBT-8835 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CRBU-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 136 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| MGX | Metagenomi Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CRSP | CRISPR Therapeutics AG | 100.00 | 2 | |
| CELU | Celularity Inc. | 100.00 | 2 | |
| IPSC | Century Therapeutics, Inc. | 100.00 | 2 | |
| KALV | KalVista Pharmaceuticals, Inc. | 100.00 | 2 | |
| ADAPY | Adaptimmune Therapeutics PLC | 100.00 | 1 | ['customer', 'supplier'] |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer', 'supplier'] |
| GSK | GSK plc | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| SGMO | Sangamo Therapeutics, Inc. | 100.00 | 2 |